Novartis Cuts Patent From Suit Over Hemophilia Drugs

Law360, New York (August 26, 2010, 2:17 PM EDT) -- A unit of Swiss drugmaker Novartis AG has agreed to drop one of three patents asserted against Wyeth in an infringement suit over hemophilia treatments ReFacto and Xyntha.

Judge T. John Ward of the U.S. District Court for the Eastern District of Texas on Tuesday signed off on a stipulated dismissal bid between Novartis Vaccines and Diagnostics Inc. and Wyeth to end their claims and counterclaims over U.S. Patent Number 7,138,505.

The parties agreed to cover their own legal costs with respect to the '505 patent....
To view the full article, register now.